What is the best management approach for erythema multiforme?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Erythema Multiforme

Erythema multiforme is a self-limited immune-mediated condition best managed by identifying and treating the underlying trigger (most commonly HSV infection), providing symptomatic relief with topical corticosteroids and antihistamines for acute episodes, and initiating prophylactic antiviral therapy for recurrent HSV-associated cases. 1, 2

Initial Assessment and Diagnosis

Distinguish erythema multiforme from Stevens-Johnson syndrome immediately, as they are separate disorders requiring different management approaches. 3

Key diagnostic features of erythema multiforme:

  • Target or iris lesions distributed symmetrically on extremities (especially extensor surfaces) spreading centripetally 2, 4
  • Lesions remain fixed for minimum of 7 days (versus urticaria which resolves within 24 hours) 2
  • May involve one mucosa (EM minor) or two or more mucosae (EM major) 5
  • Does not progress to widespread erythematous/purpuric macules with extensive blistering characteristic of SJS/TEN 3, 2

Obtain detailed history focusing on:

  • Preceding HSV infection (most common trigger) 1, 6, 5
  • Mycoplasma pneumoniae infection, especially in children 6, 4
  • Medication exposure within past 2 months, including OTC products (allopurinol, phenobarbital, phenytoin, sulfonamides, penicillins, NSAIDs, statins, TNF-α inhibitors) 3, 6
  • Recent vaccinations or immunotherapy 6

Acute Episode Management

First-Line Treatment

Stop any suspected causative medication immediately and treat identified infections before initiating symptomatic therapy. 1, 2

Topical corticosteroids (high-potency formulations) applied to cutaneous lesions for symptom control 1, 2

Oral antihistamines for pruritus and discomfort 1, 2

Mucosal Involvement

For oral or genital mucosal lesions:

  • Antiseptic or anesthetic solutions (lidocaine-based mouthwashes) for pain relief 1
  • Maintain adequate hydration 2, 4
  • Monitor for ability to maintain oral intake 2

Hospitalization is indicated when severe mucosal involvement prevents adequate oral hydration or requires intravenous fluid and electrolyte repletion 2

Recurrent Erythema Multiforme

HSV-Associated Recurrent Disease

Prophylactic antiviral therapy is first-line treatment for recurrent HSV-associated erythema multiforme. 1, 2

  • Initiate continuous suppressive antiviral therapy (acyclovir, valacyclovir, or famciclovir) 1, 6
  • Note: Topical acyclovir prophylaxis does not prevent recurrent episodes 6
  • If resistance develops to one antiviral agent, switch to an alternative virostatic drug 6

Antiviral-Refractory Cases

For patients non-responsive to antiviral prophylaxis:

Second-line options include:

  • Dapsone as immunosuppressive therapy 6
  • JAK inhibitors (emerging evidence) 6
  • Apremilast (novel option) 6
  • Other immunosuppressive agents, antibiotics (for non-HSV infectious triggers), or antimalarials 1

Systemic corticosteroids may be considered for severe recurrent cases, though evidence is limited and controversial 1, 5

Critical Clinical Pitfalls

Do not confuse erythema multiforme with Stevens-Johnson syndrome - EM has typical target lesions on acrally-distributed sites and does not progress to widespread epidermal detachment. 3, 2

Avoid using topical acyclovir for prophylaxis - it is ineffective at preventing recurrent EM episodes; systemic antiviral therapy is required. 6

Do not delay stopping suspected causative medications - immediate discontinuation is essential before initiating symptomatic treatment. 3, 1

Recognize that EM is self-limiting - most acute episodes resolve without aggressive intervention when the trigger is addressed. 1, 4

References

Research

Recent Updates in the Treatment of Erythema Multiforme.

Medicina (Kaunas, Lithuania), 2021

Research

Erythema Multiforme: Recognition and Management.

American family physician, 2019

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Oral mucosal diseases: erythema multiforme.

The British journal of oral & maxillofacial surgery, 2008

Research

Current Perspectives on Erythema Multiforme.

Clinical reviews in allergy & immunology, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.